Proof of Concept Study in Patients With Short Bowel Syndrome

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

December 31, 2020

Conditions
Short Bowel Syndrome
Interventions
DRUG

NM-002

NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)

Trial Locations (1)

90048

Research Facility One, Los Angeles

Sponsors
All Listed Sponsors
lead

9 Meters Biopharma, Inc.

INDUSTRY

NCT04379856 - Proof of Concept Study in Patients With Short Bowel Syndrome | Biotech Hunter | Biotech Hunter